## **COMMENTARY**

## MEANINGS OF $K_i$ FOR CONVENTIONAL AND ALTERNATE-SUBSTRATE INHIBITORS

THOMAS SPECTOR\*† and W. WALLACE CLELAND‡
\*Wellcome Research Laboratories, Research Triangle Park, NC 27709, U.S.A., and ‡Department of Biochemistry, University of Wisconsin, Madison, WI 53706, U.S.A.


Inhibition constants  $(K_i)$  are commonly reported to express the ability of a competitive inhibitor to decrease the velocity of an enzyme-catalyzed reaction. Unfortunately, there are frequent misinterpretations of the meanings of these constants. For example, the  $K_i$  value has been considered to be equal to the concentration of inhibitor (I) that produces 50 per cent inhibition of the reaction velocity. This is obviously incorrect because the per cent inhibition will vary with the concentration of the competing substrate. The  $K_i$  value has also been interpreted to be the dissociation constant  $(K_I)$  of the inhibitor from the EI complex. This is correct in only a few cases. The relationship between  $K_i$  and  $K_I$  can depend upon: (1) the reaction mechanism of the enzyme (i.e. the binding sequence for the substrates) (2) which substrate is being varied (3) the concentration(s) of the non-varied substrate(s), and (4) whether the inhibitor possesses any alternative substrate activity.

The following commentary provides the rationale and simple equations required to convert the variable constant,  $K_i$ , into the true constant,  $K_i$ . It also points out how studies with a competitive inhibitor can reveal reaction mechanisms, and explains how the  $K_m$  for an alternative substrate can be determined from simple competitive inhibition studies. Some of the equations and rules presented here also appear in Refs. 1–4.

Inhibitors devoid of substrate activity (dead-end inhibitors)

Determination of  $K_i$  values. Kinetic data are usually presented as double reciprocal plots of the velocity (v) versus the concentration of substrate (S) in the absence and presence of inhibitor (primary

† Author to whom all correspondence should be addressed.



SECONDARY PLOTS

SECONDARY PLOTS

I

Kii

I

Fig. 1. Graphical presentations of kinetic data.

Table 1. General Rule 1\*: To distinguish the type of inhibition

For a plot of 1/v vs. 1/S:

A dead-end inhibitor affects

(1) The 1/v axis intercept,

if I and the varied S combine with different enzyme forms and if saturation with the varied S cannot overcome the inhibition.

(2) The slope,

if (a) I and the varied S combine mutually exclusively with the same enzyme form(s), or (b) I binds before (upstream from) the varied S with an enzyme form that is reversibly connected to the form combining with the varied S (i.e. the varied S must add after I with no irreversible steps between the times of addition of both ligands).

graph of Fig. 1). This graph is preferred because most investigators are able to readily recognize the different patterns of inhibition when the data are displayed in this manner. It should be noted that the data are not accruately analyzed directly from such graphs, but rather from statistical analysis of least squares fits of the data to hyperbolas [5, 6]. Computer programs have been written to facilitate the calculations [7, 8].

The presence of a dead-end inhibitor (one that does not participate in the chemical reaction) may cause an increase in the slope and/or the intercept of a double reciprocal plot. Inhibitors that only increase the slope produce competitive inhibition and generate a family of lines that intersect on the 1/v axis (see Fig. 2A). A secondary plot of the slope

versus the concentration of the inhibitor will reveal the  $K_{i/slope)}$  or  $K_{is}$  as shown in Fig. 1. Uncompetitive inhibitors only affect the intercepts and generate a family of parallel lines. Replots of intercepts (Fig. 1) produce a  $K_{i/intercept}$  or  $K_{ii}$ . When an inhibitor increases both the slope and the intercept as in the primary plot of Fig. 1, the inhibition is noncompetitive and the lines intersect to the left of the  $1/\nu$  axis. Noncompetitive inhibition yields both a  $K_{ii}$  and a  $K_{ii}$ . These constants may or may not have equal values.

Rules for predicting patterns of inhibition and interpreting the inhibition constants. The rules for predicting the patterns of inhibition for a dead-end inhibitor are presented in Table 1. These rules are similar to those for product inhibitors [9] with the additional requirement of the upstream binding (part 2a) of the inhibitor relative to the varied substrate. Since, unlike product inhibitors, dead-end inhibitors cannot reverse a reaction sequence, they will not affect the slope if they bind after the varied substrate [2].

By definition, an irreversible step occurs when a product is released from the enzyme. This is because all velocity measurements are taken during the initial part of the reaction when the concentration of product formed is too low to permit any significant recombination with the enzyme. Saturation with a substrate will also produce an irreversible step.

The procedure for relating  $K_i$  to the dissociation constant  $(K_i)$  utilizes the rules shown in Table 2. To begin, it is most useful to make a linear diagram indicating the various enzyme forms and the sequence of addition of each substrate and the inhibitor. Next, refer to Table 2 to determine

Table 2. General Rule 2: To establish the relationship between  $K_i$  and  $K_I$ 

If the inhibitor affects	then the inhibition constant is:	and, to relate $K_i$ to $K_j$ , consider the concentration of the varied $S$ to be:	
(a) Slope	$K_{ii}$	Zero	
(b) Intercept	$ ilde{K_{ii}}$	Infinite	

Table 3. Definition of substrate constants for sequential mechanisms

Constant	Extrapolated concentration of cosubstrate	Meaning of constant		
		Ordered Steady-state	Random	
			Rapid-equilibrium	Steady-state
$K_A$	Zero	$K_d$ of A from $EA^*$	$K_d$ of A from EA	÷
$K_B$	Zero	Does not exist	$K_d$ of B from EB	÷
$K_{m(A)}$	Infinite	True $K_m$ for A	$K_d$ of A from $EAB^{\ddagger}$	True $K_m$ of A
$K_{m(B)}$	Infinite	True $K_m$ for B	$K_d$ of B from $EAB$ ‡	True $K_m$ of $B$

<sup>\*</sup>  $K_d$  = dissociation constant.

<sup>\*</sup> From Ref. 2.

<sup>†</sup> Steady-state random mechanisms occur when the rate of dissociation of the substrate(s) is slower than the  $V_{\rm max}$ . This may cause a distortion of the initial velocity patterns with resultant  $K_A$  or  $K_B$  values that are not equal to the dissociation constants of A or B from the enzyme. In the case of hexokinase [12] the rate of dissociation of glucose is slower than  $V_{\rm max}$  producing a  $K_{\rm ATP}$  that is considerably lower than the dissociation constant for ATP. Both substrates of phosphofructokinase dissociate at rates slower than the  $V_{\rm max}$  and both  $K_A$  and  $K_B$  appear lower than their respective dissociation constants [11].

<sup>‡</sup> In this case, the true  $K_m$  is also the dissociation constant.

whether the concentration of the varied substrate should be extrapolated to zero or to infinity. Finally, make the extrapolation and note on the diagram if there are any non-varied substrates remaining that will affect the binding of the inhibitor. Also note the enzyme form to which this non-varied substrate binds and the proper kinetic constant (see Table 3) that describes the association.

For most cases where the extrapolation results in the retention of only one enzyme-inhibitor species,  $K_i$  will be equal to  $K_i$  multiplied by [1 + X]. If the influence of the non-varied substrate is to impede the binding of the inhibitor, "X" will be equal to the ratio of the concentration of the substrate to its proper kinetic constant. If the non-varied substrate facilitates the binding of the inhibitor, "X" will be the inverse of this ratio. If the extrapolation from Table 2 reveals that there are no influential non-varied substrates remaining, "X" will equal zero and the  $K_i$  will directly equal the  $K_i$ .

Single substrate reactions. A competitive inhibitor and the substrate of a single substrate reaction will always bind to the same form of the enzyme. The resulting slope effects may be replotted to calculate the  $K_B$ . Rule 2 of Table 2 states that the factors required to relate the  $K_B$  to the  $K_I$  are revealed by considering the concentration of the substrate to be zero. Since there are no cosubstrates, in the absence of the substrate, there is nothing left to affect the binding of the inhibitor to the enzyme. Therefore, for all single substrate reactions, the  $K_B$  of a competitive inhibitor is equivalent to its dissociation constant (Equation 1.0).

$$K_{is} = K_I \tag{1.0}$$

Two substrate reactions. It is more common for enzymes to catalyze reactions involving two substrates rather than just one. The additional substrate may confer some complexity on the relationships between  $K_i$  and  $K_I$ . The nature of this relationship is dependent upon the mechanism by which the substrates bind to the enzyme. Basically, there are two ways for substrates to do this. The sequential mechanism requires that all substrates be simultaneously bound to the enzyme before any product is formed. The second mechanism requires that the first substrate bind, "donate" a chemical group to the enzyme, and depart. The next substrate then binds, accepts that chemical group, and it too departs. The enzyme thus fluctuates or ping-pongs between the unmodified and the chemically modified forms and hence the name ping-pong mechanism.


(a) Sequential mechanisms. The sequential mechanism is referred to as ordered if the substrates bind in a compulsory step-wise fashion. That is, substrate A binds first, and then substrate B will bind to the EA complex to form the ternary EAB complex. The mechanism is random if either A or B binds first. Sequential mechanisms are further divided into rapid-equilibrium and steady-state subclasses. Detailed explanations of these subclasses can be

found in Refs. 10 and 11. The following discussion will exclude the uncommon rapid-equilibrium ordered mechanism.

There are a number of constants that can be obtained from the sequential mechanisms. These constants are defined in Table 3\*. The first two constants are called  $K_A$  and  $K_B$  and in most cases represent dissociation constants of substrate A or substrate B from their respective complex with enzyme.  $K_A$  and  $K_B$  are the constants that exist when the concentration of the cosubstrates are extrapolated to zero. The  $K_{m(A)}$  and  $K_{m(B)}$  constants are the true Michaelis constants and exist when the concentration of the cosubstrates are extrapolated to infinity. For the rapid-equilibrium random mechanism, these constants are also the dissociation constants of A or B from the ternary EAB complex.

(i) Ordered sequential mechanisms. The ordered sequence is shown in Diagram 1.0. P and Q are the products of the reaction.

Case 1.1 (Diagram 1.1)—The inhibitor, l, competes with A for binding to free enzyme, E, but



cannot promote the binding of B. Therefore, there is no formation of an EIB complex. The less common case where EIB is formed will be discussed below (for the most part, inhibitors do not usually mimic substrate A well enough to convert the enzyme into a form that will accept substrate B). Consider the inhibition, with A as the varied substrate. Since A and I both bind to enzyme form E, there will be a slope effect, and only a slope effect. The inhibition will be competitive and a  $K_B$  can be obtained. The rule from Table 2 states to extrapolate to zero A. Without A, B cannot bind. So with no influence of B on the  $K_B$ , the  $K_B$  is equal to the dissociation constant ( $K_I$ ) (Equation 1.1a).

$$K_{is} = K_I \tag{1.1a}$$

This relationship is true for any inhibitor that is competitive with the first substrate of an ordered sequential mechanism regardless of the concentration of the second (non-varied) substrate.

When B is the varied substrate (A not saturating), the results will be different. Since B and I bind to different forms, and saturation by B would not nullify the inhibition, there is an intercept effect. As I binds to an enzyme form that lies upstream to B (that is, before) and is not separated from it by any irreversible steps, there will also be a slope effect. The inhibition will therefore be noncompetitive and both a  $K_{ii}$  can be determined. The factors relating the  $K_{ii}$  to the  $K_{I}$  are determined by considering the

<sup>\*</sup> The convention used here is different from Cleland's which denotes the dissociation constants from the binary complexes as  $K_{ia}$  and  $K_{ib}$  and the true  $K_{m}$ 's as  $K_{a}$  and  $K_{b}$ .

concentration of B to be zero (from Table 2). It can be seen from Diagram 1.1 that with B absent substrate A will still impede the binding of I. Furthermore, the enzyme form to which A binds is E and the kinetic constant which describes this association (from Table 3) is  $K_A$ . Therefore, as shown in Equation 1.1b,  $K_B$  is equal to  $K_I$  multiplied by  $[1 + A/K_A]$  and its value will increase as the concentration of A is increased relative to its dissociation constant  $(K_A)$ . The true  $K_I$  may be calculated from this equation.

$$K_{ii} = K_f(1 + A/K_A)$$
 (1.1b)

The  $K_{ii}$  is related to the  $K_I$  by imagining the concentration of B to be infinite (Table 2). This will convert all EA to the EAB complex. The constant that describes the association of A with the enzyme under these conditions is  $K_{m(A)}$  (Table 3). Thus, it is the ratio of A to its true  $K_m$  that is included in the equation to calculate  $K_I$  from  $K_{ii}$  (Equation 1.1c).

$$K_{ii} = K_{I} (1 + A/K_{m(A)})$$
 (1.1c)

The dissociation constant of an inhibitor competitive with the first substrate of an ordered mechanism can therefore be determined either directly from the  $K_{is}$  of the competitive inhibition or indirectly from either the  $K_{is}$  or the  $K_{ii}$  of the noncompetitive inhibition versus the second substrate. To be consistent with this mechanism, all three values must be equal. Figure 2 shows an example of this type of inhibition where GMP reductase is inhibited

by XMP (xanthosine 5'-monophosphate) [13]. The first substrate of this ordered sequence is GMP. The second substrate is NADPH. As seen in Fig. 2A, XMP is competitive versus GMP, the first substrate, and, in 2C, is noncompetitive versus NADPH, the second substrate. The three determinations of the dissociation constant in this situation produced very similar values. Another interesting feature of this type of inhibition is that since I and A compete for binding, the effect of increasing I would be virtually identical to the effect of decreasing A. Therefore. the increase of I in Fig. 2C causes the family of lines to pivot at a locus that is exactly identical to the locus at which the family of lines pivots in Fig. 2B when A is decreased in the absence of any inhibitor. Therefore, both the vertical and horizontal coordinates of the common point of intersection of the lines in Fig. 2B are the same as those of the lines in Fig. 2C.

Case 1.2 (Diagram 1.2)—I competes with B for binding to EA. Of course this will produce com-

petitive inhibition versus B. The extrapolation to zero B shows that the binding of the inhibitor will be influenced by the binding of substrate A to form




Fig. 2. Inhibition of GMP reductase (schematically reproduced from Ref. 13).


E. Since I binds to the EA complex, its binding is dependent upon the prior binding of A (i.e. A facilitates the binding of I). Therefore,  $K_{ii}$  is equal to  $K_{I}$  multiplied by  $[1 + K_A/A]$ , and the  $K_{ii}$  will decrease as the concentration of A increases (Equation 1.2a).

$$K_{is} = K_I (1 + K_A/A)$$
 (1.2a)

An examination of the inhibition versus A shows that A and I combine with different forms of the enzyme and saturation by A does not overcome the inhibition, but actually enhances it. Thus, there is an intercept effect. There is no slope effect, however, because the inhibitor binds after or downstream from A (when A is extrapolated to zero, there is no EA for I to combine with). The inhibition is therefore uncompetitive. To determine the factors that relate  $K_{ii}$  to  $K_I$ , consider the concentration of A to be infinite. Therefore, it is the true  $K_m$  for B and not the dissociation constant of B that enters into the calculation (Equation 1.2b).

$$K_{ii} = K_I (1 + B/K_{m(B)})$$
 (1.2b)


Case 1.3 (Diagram 1.3)—I competes with A for binding to E and EIB is formed. This case is similar to Case 1.1 except that I mimics A well enough to promote the binding of B. Formation of an EIB



D1.3

complex is readily detectable because the inhibitor will induce substrate-inhibition when B is the varied substrate. As mentioned above, this case is uncommon and will not be discussed in detail here. A good discussion and example of this type of inhibition can be found in Ref. 14 which describes the inhibition of thymidylate synthetase by bromodeoxyUMP.

(ii) Random sequential mechanisms. The random binding mechanism shown in Diagram 2.0 illustrates




D2.0

D2.1

that either substrate A or B can bind first in the process of forming the EAB complex.

Case 2.1 (Diagram 2.1)—I competes with A for binding to either E or the EB complex. In this



situation, there are two dissociation constants.  $K_I$ describes the affinity of I towards E and  $K_i^*$  describes the affinity of I towards the EB complex. Thus, the  $K_{is}$  from the competitive inhibition versus A is a composite of both of these dissociation constants. At low B, E will be available to I and  $K_I$  will dominate. At saturating B, E will be forced into the EBcomplex and  $K_i^*$  will dominate. At in-between (real life) concentrations of B,  $K_{is}$  is represented by Equation 2.1a, which contains two unknowns and thus requires that  $K_{is}$  be measured at several different concentrations of B to determine both  $K_l$  and  $K_l^*$ . The situation is simplified by examining the inhibition versus B at non-saturating A. This results in non-competitive inhibition and produces a  $K_{is}$  and a  $K_{ii}$ . It can be seen in Equation 2.1b that the  $K_{i}$  is discernible from the  $K_{is}$  (B extrapolated to zero) and in Equation 2.1c that the  $K_i^*$  is obtained from the  $K_{ii}$  ( $\vec{B}$  extrapolated to infinity).


$$K_{s} = \frac{K_{l} (1 + B/K_{B})}{[1 + (K_{l}/K_{l}^{*}) (B/K_{B})]}$$
(2.1a)

$$K_{is} = K_{I} (1 + A/K_{A})$$
 (2.1b)

$$K_{ii} = K_i^* (1 + A/K_{m(A)})$$
 (2.1c)

Since random mechanisms are symmetrical, a competitive inhibitor of B is analyzed by substituting B for A in Equations 2.1b and 2.1c. An example of this type of analysis can be found in Ref. 15.

Case 2.2 (Diagram 2.2)—I competes with A and



D2.2


B for binding to E. When I is large enough to cover the binding sites for both A and B, it will produce competitive inhibition with respect to either substrate.

Equations 2.2a (A is varied) and 2.2b (B is varied) show that the  $K_{is}$  is affected by the concentration of non-varied substrate relative to its dissociation constant. This type of inhibition is exemplified in Ref. 16.

$$K_{is} = K_I (1 + B/K_B)$$
 (2.2a)

$$K_{is} = K_I (1 + A/K_A)$$
 (2.2b)

(b) Ping-pong mechanism. Diagram 3.0 illustrates



the typical ping-pong mechanism. Here F is the modified and E the unmodified form of the enzyme. Case 3.1 (Diagram 3.1)—I competes with A for binding to E. The  $K_n$  from this inhibition is equal to the  $K_I$  because at zero A, there is no form F available for B to bind (Equation 3.1a).

$$K_{is} = K_{i} \tag{3.1a}$$

An examination of the inhibition versus B reveals that I and B bind to different forms of the enzyme and saturation by B will not overcome the inhibition. An intercept effect is therefore created. However, although I binds upstream from B, there is no slope effect because the binding of I and B is separated by the release of P which is an irreversible step. So, the inhibition is uncompetitive. At infinite B, it is the  $K_{m(A)}$  that relates  $K_u$  to  $K_l$  (Equation 3.1b).

$$K_u \simeq K_I (1 + A/K_{m(A)})$$
 (3.1b)

Case 3.2: I competes with B for binding to F. The second half of the reaction sequence has the same properties as the first half. Thus, a competitive inhibitor with respect to B will be treated identically to a competitive inhibitor of A. That is, the  $K_B$  from the competitive inhibition is equal to the  $K_I$  (Equation 3.2a) and the  $K_B$  from the uncompetitive inhibition versus A is related to the  $K_I$  by the true  $K_{m(B)}$  term as shown in Equation 3.2b. The inhibition of transcarboxylase [17] provides an example of inhibitors of this type.

$$K_b = K_t \tag{3.2a}$$

$$K_u = K_L (1 + B/K_{m(B)})$$
 (3.2b)

Use of inhibitors to determine reaction mechanisms. It becomes obvious that to relate  $K_{is}$  or  $K_{ii}$  to  $K_I$ , the reaction mechanism must first be known. However, on the brighter side, the patterns of inhibition themselves may reveal the mechanism and thereby create a self-sufficient system of analysis. Fromm [3, 18] has pointed out that dead-end inhibitors produce inhibition patterns that are unique for each reaction mechanism and, therefore, can be used as powerful diagnostic tools. For example, as described by Fromm and above, a competitive inhibitor of substrate A produces noncompetitive inhibition with B and a competitive inhibitor of B produces uncompetitive inhibition with A in an ordered sequential mechanism (Cases 1.1 and 1.2). The patterns are competitive, noncompetitive and competitive, noncompetitive for similar experiments with a small inhibitor and a random mechanism (Case 2.1). A large inhibitor produces competitive inhibition with both A and B of the random mechanism (Case 2.2). Finally, the patterns are competitive, uncompetitive and competitive, uncompetitive with the ping-pong mechanism (Cases 3.1 and 3.2). Thus, either two or four inhibition experiments may establish patterns that uniquely define the reaction mechanism.

## Alternate-substrate inhibitors

Alternative substrates are compounds which can replace the normal substrate of an enzyme-catalyzed reaction. The nomenclature is modified for these compounds. As depicted in Equations 4.1 and 4.2. the alternative substrate  $S^*$  replaces S and produces the alternate product  $P^*$  with a maximal velocity of  $V^*$ . C is the common cosubstrate and Q the common product. When  $S^*$  is used as an inhibitor, it is critical to measure only the unique product produced from S. This product is circled in Equation 4.1. If the formation of Q, or the sum of P and  $P^*$  is measured. the velocity will be a combination of the two reactions and non-linear double reciprocal plots may result. When the ratio of  $V/V^*$  is greater than about 15, the velocity of the reaction with  $S^*$  is not a significant contribution, and  $S^*$  can be considered a dead-end inhibitor and will give the patterns already discussed above.

$$S + C \xrightarrow{\Lambda} P + Q \tag{4.1}$$

$$S^* + C \xrightarrow{V^*} P^* + Q \tag{4.2}$$

Patterns of inhibition. Table 4 states that  $S^*$  will produce competitive inhibition versus S and noncompetitive inhibition versus C. This is true for any mechanism regardless of the binding order of S and C. There is no uncompetitive inhibition with alternate-substrate inhibitors of significant  $V^*$ . The observation of uncompetitive inhibition means that  $V^*$  is negligible and  $S^*$  is behaving as a dead-end inhibitor.

Kinetic constants of  $S^*$ . The  $K_{s}$  from the competitive inhibition of S by  $S^*$  is equivalent to the apparent  $K_m$  for  $S^*$  at the fixed concentrations of the cosubstrate(s) (Equation 4.3).

$$K_n = K'_{m(S)} \tag{4.3}$$

The use of alternative substrates as competitive inhibitors is a very efficient way to conserve enzyme when determining apparent  $K_m$  values for alternative substrates with low  $V^*$  values (e.g. Ref. 13). Alternative substrates may also be studied as inhibitors to ascertain their true constants.

If  $V^*$  approaches zero, alternate-substrate inhibitors are analyzed in the same manner as dead-end

Table 4. Alternate-substrate inhibitors\*

When an alternative substrate ( $S^*$ ) is used as an alternatesubstrate inhibitor, it will produce competitive inhibition versus the substrate it replaces (S) and noncompetitive inhibition versus the cosubstrates, provided that the velocity contribution from  $S^*$  is not measured.

<sup>\*</sup>From Ref. 2.

inhibitors and dissociation constants are obtained. If  $V^*$  is significant, the alternative substrate's  $K_{S^*}$  (concentration of C extrapolated to zero) and/or its true Michaelis constant,  $K_{m(S^*)}$  (C extrapolated to infinite), may be calculated by the following equations.

Ordered sequential mechanisms. Because  $S^*$  diverts the flux of the reaction, the double reciprocal plots may not be linear. For this reason, discussions of this mechanism are not within the scope of this manuscript, but can be found in Refs. 2 and 4.

Random sequential mechanisms. An alternatesubstrate inhibitor replacing either substrate will produce noncompetitive inhibition versus the substrate it does not replace. The  $K_{S^*}$  is obtained from the  $K_{is}$  as shown in Equation 4.4. The  $K_{m(S^*)}$  is obtained from the  $K_{ii}$  (Equation 4.5). The meanings of  $K_{S^*}$  and  $K_{m(S^*)}$  are described in Table 3.

$$K_{is} = K_{S^*} (1 + S/K_S)$$
 (4.4)

$$K_n = K_{m(S^*)} (1 + S/K_{m(S)})$$
 (4.5)

Ping-pong mechanisms. The true  $K_m$  for  $S^*$  can be obtained from the  $K_n$  of the noncompetitive inhibition versus the cosubstrate. The relationship is shown in Equation 4.6.

$$K_{ii} = K_{m(S^*)} (1 + S/K_{m(S)})$$
 (4.6)

Acknowledgement—the authors acknowledge and appreciate Dr. J. A. Fyfe for his helpful discussions during the preparation of this manuscript.

## REFERENCES

- 1. T. F. Thompson, and H. S. Bachelar, *Analyt. Biochem.* **71**, 507 (1976).
- I. H. Segel, in *Enzyme Kinetics*, Chapters VI and IX. John Wiley, New York (1975).
- 3. H. J. Fromm, *Initial Rate Enzyme Kinetics*, Chapters III-VII. Springer, New York, (1975).
- 4. W. W. Cleland, Adv. Enzymol. 45, 277 (1977).
- 5. G. N. Wilkinson, Biochem. J. 80, 324 (1961).
- 6. W. W. Cleland, Adv. Enzymol. 29, 1 (1967).
- 7. W. W. Cleland, Nature Lond. 198, 463 (1963).
- 8. W. W. Cleland, Meth. Enzym. 63A, 103 (1979).
- 9. W. W. Cleland, Biochim. biophys. Acta 67, 188 (1963).
- 10. W. W. Cleland, Biochim. biophys. Acta 67, 104 (1963).
- 11. J. Bar-Tana and W. W. Cleland, J. biol. Chem. 249,
- 1271 (1974).
  12. K. D. Danenberg and W. W. Cleland, *Biochemistry*
- **14**, 28 (1975). 13. T. Spector, T. E. Jones and R. L. Miller, *J. biol. Chem.*
- 254, 2308 (1979).14. P. V. Danenberg and K. D. Danenberg, *Biochemistry* 17, 4018 (1978).
- J. Bar-Tana and W. W. Cleland, J. biol. Chem. 249, 1263 (1974).
- D. V. Santi, P. B. Dananberg and P. Satterly, Biochemistry 10, 4804 (1971).
- 17. D. B. Northrop, J. biol. Chem. 244, 5808 (1969).
- 18. H. J. Fromm, Meth. Enzym. 63A, 467 (1979).